Molecular events in neuroendocrine prostate cancer development

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a su...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature reviews. Urology Ročník 18; číslo 10; s. 581 - 596
Hlavní autoři:	Wang, Yong, Wang, Yu, Ci, Xinpei, Choi, Stephen Y C, Crea, Francesco, Lin, Dong, Wang, Yuzhuo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.10.2021
Témata:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - pathology Androgen Antagonists - therapeutic use Androgens Antineoplastic Agents - therapeutic use Cell Transdifferentiation Disease Progression Humans Male Neuroendocrine Tumors - genetics Neuroendocrine Tumors - metabolism Neuroendocrine Tumors - pathology Platinum Compounds - therapeutic use Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - metabolism
ISSN:	1759-4812, 1759-4820, 1759-4820
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!